Research programme: microRNA therapeutics - GlaxoSmithKline/Regulus Therapeutics

Drug Profile

Research programme: microRNA therapeutics - GlaxoSmithKline/Regulus Therapeutics

Alternative Names: miR-122 inhibitors - GlaxoSmithKline/Regulus; miR-146 inhibitors - GlaxoSmithKline/Regulus; miR-155 inhibitors - GlaxoSmithKline/Regulus; miR-181a inhibitors - GlaxoSmithKline/Regulus

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Regulus Therapeutics LLC
  • Developer GlaxoSmithKline; Regulus Therapeutics
  • Class MicroRNAs
  • Mechanism of Action MicroRNA inhibitors; MIRN122 microRNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hepatitis C; Inflammation

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-C in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA (Parenteral)
  • 09 May 2014 Preclinical development is ongoing for Inflammation in USA (Regulus 10-Q)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top